{"&cites=400146355432723290&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy":[{"title":"Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications","url":"https://www.tandfonline.com/doi/abs/10.1586/erp.10.72","authors":["B Godman","B Godman W Shrank","B Godman W Shrank M Andersen","B Godman W Shrank M Andersen C Berg…"],"year":2010,"numCitations":166,"pdf":"http://www.academia.edu/download/51475950/Comparing_policies_to_enhance_prescribin20170123-25558-8t52q9.pdf","citationUrl":"http://scholar.google.com/scholar?cites=14266846914305676945&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:kVYR-K0F_sUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14266846914305676945&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Taylor & Francis","p":1,"exp":1596876810197},{"title":"Policies to enhance prescribing efficiency in Europe: findings and future implications","url":"https://www.frontiersin.org/articles/10.3389/fphar.2010.00141","authors":["B Godman","B Godman W Shrank","B Godman W Shrank M Andersen","B Godman W Shrank M Andersen C Berg…"],"year":2011,"numCitations":125,"pdf":"https://www.frontiersin.org/articles/10.3389/fphar.2010.00141","citationUrl":"http://scholar.google.com/scholar?cites=9011910708921240118&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:NgrK6Aq9EH0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9011910708921240118&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"frontiersin.org"},{"title":"The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine …","url":"https://www.sciencedirect.com/science/article/pii/S131901641300128X","authors":["MA Hassali","MA Hassali AA Alrasheedy","MA Hassali AA Alrasheedy A McLachlan…"],"year":2014,"numCitations":119,"pdf":"https://www.sciencedirect.com/science/article/pii/S131901641300128X","citationUrl":"http://scholar.google.com/scholar?cites=2446105825901726494&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:Hsvi40lQ8iEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2446105825901726494&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Elsevier"},{"title":"Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?","url":"https://www.tandfonline.com/doi/abs/10.1586/17512433.2015.990380","authors":["B Godman","B Godman RE Malmström","B Godman RE Malmström E Diogene…"],"year":2015,"numCitations":112,"pdf":"https://strathprints.strath.ac.uk/50989/6/Godman_etal_ERCP_2014_Are_new_models_needed_to_optimise_the_utilization.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10217696261251741224&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:KDa_Kp2MzI0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10217696261251741224&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Taylor & Francis"},{"title":"Use of generics—a critical cost containment measure for all healthcare professionals in Europe?","url":"https://www.mdpi.com/1424-8247/3/8/2470","authors":["B Godman","B Godman W Shrank","B Godman W Shrank B Wettermark","B Godman W Shrank B Wettermark M Andersen…"],"year":2010,"numCitations":104,"pdf":"https://www.mdpi.com/1424-8247/3/8/2470/pdf","citationUrl":"http://scholar.google.com/scholar?cites=15396177834864189607&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:p6DSGSs2qtUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15396177834864189607&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"mdpi.com"},{"title":"Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs","url":"https://www.frontiersin.org/articles/10.3389/fphar.2013.00039/full","authors":["R Malmstrom","R Malmstrom B Godman","R Malmstrom B Godman E Diogene…"],"year":2013,"numCitations":88,"pdf":"https://www.frontiersin.org/articles/10.3389/fphar.2013.00039/full","citationUrl":"http://scholar.google.com/scholar?cites=4795503353889609289&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:SdbIh-QMjUIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4795503353889609289&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"frontiersin.org"},{"title":"European countries with small populations can obtain low prices for drugs: Lithuania as a case history","url":"https://www.tandfonline.com/doi/abs/10.1586/erp.11.24","authors":["K Garuoliene","K Garuoliene B Godman","K Garuoliene B Godman J Gulbinovič…"],"year":2011,"numCitations":86,"pdf":"https://www.researchgate.net/profile/Bjorn_Wettermark/publication/51217760_European_countries_with_small_populations_can_obtain_low_prices_for_drugs_Lithuania_as_a_case_history/links/5676c6f008ae0ad265c59fe4.pdf","citationUrl":"http://scholar.google.com/scholar?cites=6344570488949834669&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:rQNIpj5xDFgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6344570488949834669&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Taylor & Francis"},{"title":"Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations","url":"https://link.springer.com/article/10.1007/s00228-013-1497-5","authors":["L Björkhem"],"year":2013,"numCitations":83,"pdf":"http://www.csb.cat/wp-content/uploads/2016/10/Reading-Bjorkhem-Bergman-et-al-Interface-Management-EJCP-2013-4.pdf","citationUrl":"http://scholar.google.com/scholar?cites=11387714816382321422&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:DsPrcUpKCZ4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11387714816382321422&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Springer"},{"title":"Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future","url":"https://www.tandfonline.com/doi/abs/10.1586/erp.11.42","authors":["L Vončina","L Vončina T Strizrep","L Vončina T Strizrep B Godman…"],"year":2011,"numCitations":81,"pdf":"https://www.researchgate.net/profile/Iain_Bishop/publication/51561264_Influence_of_demand-side_measures_to_enhance_renin-angiotensin_prescribing_efficiency_in_Europe_Implications_for_the_future/links/54ddde050cf2814662eb9cb8.pdf","citationUrl":"http://scholar.google.com/scholar?cites=3093947839925153392&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:cG5TACvp7yoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3093947839925153392&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Taylor & Francis"},{"title":"Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries","url":"https://www.tandfonline.com/doi/abs/10.1586/14737167.2013.820956","authors":["B Godman","B Godman I Bishop","B Godman I Bishop AE Finlayson…"],"year":2013,"numCitations":80,"pdf":"http://www.academia.edu/download/42150090/Reforms_and_initiatives_in_Scotland_in_r20160205-30232-pbgllg.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10743432046301021574&as_sdt=2005&sciodt=0,5&hl=en&scioq=pharmaceutical+policy","relatedUrl":"http://scholar.google.com/scholar?q=related:hgVSZIZWGJUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10743432046301021574&hl=en&as_sdt=2005&sciodt=0,5&scioq=pharmaceutical+policy","publication":"Taylor & Francis"}]}